In vivo lung reconditioning by the use of Steen solution in a model of hemorrhagic shock

• Grant number: 12/01483-2
• Support type: Scholarships in Brazil - Scientific Initiation
• Effective date (Start): April 01, 2012
• Effective date (End): March 31, 2013
• Field of knowledge: Health Sciences - Medicine - Surgery
• Principal researcher: Paulo Manuel Pêgo-Fernandes
• Grantee: Leandro Ryuchi Iuamoto
• Home Institution: Instituto do Coração Professor Euryclides de Jesus Zerbini (INCOR). Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil

Abstract

The lung is the organ that deteriorates faster in the donor organ and prolonged hypotension, present in most of these patients, causes pulmonary interstitial edema, activation of inflammatory mediators and formation of hyaline membrane, leading to acute lung injury. The "pulmonary reconditioning" through preservation solutions has emerged as an innovative technique for to make feasible organs for transplantation and discarded before reducing primary graft dysfunction, with positive impact on morbidity and mortality in transplant patients. This study aims to evaluate ex vivo the intravenous use of an lung perfusion solution (solution Steen ®, Vitrolife, Sweden) in the functional recovery of the lungs; this model is unique in world literature, also enabling future research lines. Methods. Using experimental models (30 rats of the Sprague-Dawley) with acute lung injury from hypotension / hypovolemia randomized into four groups (sham, control and Steen solution), we'll proceed to the intravenous administration of Steen solution and, after removal of the cardiopulmonary block, quantify the effectiveness of solution in the improvement of ventilatory parameters in an perfusion of ex vivo rat lungs "IPL-2" (Isolated Perfused Rat or Guinea Pig Lung System, Harvard Apparatus, Holliston, Massachusetts, USA , Hugo Sachs Elektronik, Germany). We will assess the impact on gas exchange. Reproduction of this model in humans will allow a further step in the management of patients lung donors. (AU)